Last updated
KLOW and GLOW are marketed repair-and-skin blends that share a common base — GHK-Cu, BPC-157, and TB-500. The practical difference is one component: KLOW adds KPV, the anti-inflammatory C-terminal tripeptide of α-MSH, making it a four-peptide stack versus GLOW’s three.
Both are physical mixtures, not single molecules, and neither has been studied as a blend. Their composition and ratios are vendor-defined and not standardized, so this comparison is about what the stacks are designed to cover, not about proven combined effects. Every component is a research compound profiled on its own page.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | KLOW | GLOW |
|---|---|---|
| What it is | A four-peptide physical blend | A three-peptide physical blend |
| Shared base | GHK-Cu + BPC-157 + TB-500 | GHK-Cu + BPC-157 + TB-500 |
| Added component | KPV (anti-inflammatory tripeptide) | None — base three only |
| Design intent | Angiogenesis, migration, skin/matrix, and inflammation | Angiogenesis, migration, and skin/matrix |
| Composition | Vendor-defined, not standardized | Vendor-defined, not standardized |
| Studied as a blend | No — per-component evidence only | No — per-component evidence only |
| FDA approval | None | None |
GLOW pairs the copper tripeptide GHK-Cu — studied for collagen synthesis and extracellular-matrix remodeling — with the two most-referenced repair peptides, BPC-157 (angiogenesis and growth-factor signaling) and TB-500 (actin-driven cell migration). The idea is to cover skin and soft-tissue repair in a single vial.
KLOW is generally the same three peptides plus KPV. KPV is the C-terminal fragment of α-MSH that retains anti-inflammatory activity — associated with NF-κB-pathway inhibition — without the pigmentary effect. Adding it is meant to bring an inflammation-dampening element alongside the repair and skin peptides. Whether that fourth component changes real-world results is untested: like GLOW, KLOW has no controlled study as a mixture, and the more peptides share one solution, the more its stability and net effect depart from anything characterized.
GLOW and KLOW share the same GHK-Cu / BPC-157 / TB-500 base; KLOW adds KPV to bring an anti-inflammatory component into the stack. That single difference is the whole comparison. Neither is a single molecule, neither is studied as a blend, and both have vendor-defined, non-standardized compositions — so the honest read is that KLOW is GLOW plus KPV, with all the same uncertainties and one more component’s worth of them. For the underlying science, see each component’s monograph. This page is a research and educational reference.
Both blends share GHK-Cu, BPC-157, and TB-500. KLOW adds a fourth component, KPV, an anti-inflammatory tripeptide. GLOW is the three-peptide version; KLOW is the four-peptide version.
No. The individual components are studied, mostly in preclinical work, but neither KLOW nor GLOW has been tested as a mixture in controlled research.
No — the exact components and ratios are defined by the vendor and are not standardized across suppliers, so treat any stated formula as vendor-specific.
No. None of the components is FDA-approved, and neither blend is either. This page is a research and educational reference.
Mechanism, evidence, and trade-offs between KLOW and GLOW — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.